00:53 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of the HGF/SF/c-MET/Src and SHH/IGF-1/IGF1R pathways could help treat pancreatic ductal adenocarcinoma (PDAC). In human PDAC cell lines, the Src inhibitor Sprycel dasatinib or an...
07:00 , Sep 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Annexin A2 (ANXA2); semaphorin 3D (SEMA3D)

Cancer INDICATION: Pancreatic cancer In vitro and mouse studies suggest inhibiting ANXA2 or SEMA3D could help treat metastatic pancreatic ductal adenocarcinoma (PDAC). In human PDAC samples, high SEMA3D levels were associated with early disease recurrence and widespread...
08:00 , Mar 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Annexin A2 (ANXA2); helicase-like transcription factor (HLTF; SMARCA3); S100 calcium binding protein...
07:00 , Aug 23, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Non-small cell lung cancer (NSCLC) Annexin A2 (ANXA2) Patient sample, mouse and cell culture studies suggest inhibiting...
08:00 , Nov 17, 2011 |  BC Innovations  |  Strategy

MD Anderson's private screening

Less than two years after The University of Texas MD Anderson Cancer Center carved up the IP for its in vivo phage display screening platform, the two biotech licensees have preclinical proof-of-concept data and preliminary...
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Annexin A2 (ANXA2) Mouse and patient tissue studies suggest antagonizing ANXA2 could help treat gliomas....
07:00 , Sep 10, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Antiphospholipid syndrome (APS) ...
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

TM601: Phase I data

Data from 6 patients with recurrent glioblastoma in a Phase I trial showed that unlabeled TM601 was well tolerated, with intratumoral hemorrhage possibly related to treatment. TM601 reduced relative cerebral blood flow (rCBF) and/or relative...